On-Treatment Blood Pressure and Dose-Dependent Effects of ARNI in Heart Failure with Reduced Ejection Fraction: Insights from a Multicenter Registry
Résumé
Abstract Achieving the target dose of angiotensin receptor-neprilysin inhibitor (ARNI) in heart failure with reduced ejection fraction (HFrEF) remains challenging due to concerns related to hypotension. This study investigated the dose-dependent effects of ARNI based on on-treatment blood pressure (BP). Using 1,097 HFrEF patient data from a multicenter HF registry who received ARNI for at least 6 months, subjects were stratified into low-dose (<100 mg/day; n=249) and intermediate- to high-dose (≥100 mg/day; n=848) groups based on the average ARNI dose over a 1-year period. Changes in echocardiographic features and clinical outcomes were assessed, considering on-treatment BP profiles (high-BP [average systolic BP ≥110 mmHg] and low-BP [<110 mmHg]). Low-BP was an independent predictor for low-dose ARNI. Echocardiographic improvements were observed in both dose groups, with more pronounced changes in the intermediate- to high-dose group. Over a median follow-up of 3.1 years, the low-dose group demonstrated an increased risk of mortality compared to the intermediate- to high-dose group. These trends were consistently observed in both BP profiles. In conclusion, low-dose ARNI leads to insufficient improvements in echocardiographic parameters and worse clinical outcomes regardless of on-treatment BP, suggesting the importance of optimal dose titration, which should not be discouraged by low-BP response.
Citer ce document
Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)
Accès au document
Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter
Voir l'article sur le site de la revueLicence et provenance
Licence : CC BY
Notice moissonnée depuis OpenAlex le 27/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →